Graham Robinson
Graham Robinson is the head of the Boston Mergers and Acquisitions Group and also serves as a member of the Policy Committee, Skadden’s governing body. He focuses his practice on mergers, acquisitions and other transactions in the pharmaceutical, medical device and technology industries in the U.S. and internationally.

Bio

Mr. Robinson regularly represents public and private companies, as well as private equity and venture capital funds in acquisitions and divestitures, both negotiated and contested. He has significant experience advising companies in preparing for and responding to unsolicited acquisition proposals, as well as advising companies in dealing with activist investors. Mr. Robinson also advises companies in pharmaceutical and medical device collaborations, and issuers and underwriters in connection with initial public offerings and other corporate finance transactions.

Mr. Robinson’s representations include:

  • WeWork in its offering of series G preferred stock to SoftBank Group;
  • WeWork Japan in its joint venture with SoftBank Group;
  • WeWork Greater China Holding Co. in its $500 million offering of series A preferred shares to Hony Capital and SoftBank Group;
  • Merrimack Pharmaceuticals in its pending asset sale to Ipsen for up to $1.025 billion;
  • Tobira Therapeutics in its sale to Allergan for up to $1.7 billion;
  • Qlik Technologies in its sale to Thoma Bravo for $3 billion;
  • Gilead Sciences in its acquisition of Nimbus Apollo for up to $1.2 billion;
  • Almirall, S.A. in its acquisition of an option to acquire ThermiGen LLC, and later exercise of that option;
  • Annapurna Therapeutics in its combination with Avalanche Biotechnologies;
  • WeWork Cos. in its offering of series F preferred stock to Hony Capital, Legend Holdings and other investors;
  • Gilead Sciences in its collaboration with, and $425 million equity investment in, Galapagos NV;
  • NPS Pharmaceuticals in its $5.2 billion sale to Shire. Mr. Robinson was named as a “Dealmaker of the Week” by The American Lawyer for his role on this transaction (January 16, 2015);
  • Strongbridge Biopharma in its redomiciliation from Sweden to Ireland by means of an exchange offer in connection with its U.S. initial public offering;
  • Almirall, S.A. in its strategic investment in Suneva Medical;
  • Dendreon Corporation in its Chapter 11 filing and proposed restructuring of $620 million of convertible notes, its sale of Provenge and other assets to Valeant for $495 million, and in the sale of its New Jersey immunotherapy manufacturing facility to Novartis for $43 million;
  • Gilead Sciences in its acquisition of Phenex Pharmaceuticals for up to $470 million;
  • Veloxis Pharmaceuticals in connection with its lawsuit against the FDA relating to the approval of the drug Envarsus XR;
  • J.P. Morgan and Citigroup as lead underwriters in the $78 million initial public offering of Prosensa Holding B.V.;
  • Covidien Ltd. in its investment in and acquisition of an option to acquire privately held medical device company FIRE1;
  • Covidien Ventures in numerous investments in private medical device companies;
  • Tranzyme Pharma in its merger with Ocera Therapeutics and related financing transaction;
  • Celltrion GSC Co., Ltd. and Celltrion Holdings Co., Ltd. in their sale of 4.42 million shares of Celltrion, Inc. to an affiliate of Temasek Holdings for $129 million;
  • Savient Pharmaceuticals in its $120 million sale to Crealta Pharmaceuticals;
  • Rhythmia Medical in its sale to Boston Scientific for up to $265 million;
  • Skyworks Solutions in its acquisition of SiGe Semiconductor for up to $275 million;
  • Prism Pharmaceuticals in its sale to Baxter International for up to $338 million;
  • Arbor Networks in its sale to Danaher Corporation;
  • Sapphire Therapeutics in its sale to Helsinn Healthcare;
  • Analog Devices in its acquisition of Lyric Semiconductor;
  • Progress Software in its $162 million acquisition of IONA Technologies PLC;
  • PerkinElmer, Inc. in its $600 million acquisition of Caliper Life Sciences, its $300 million acquisition of ViaCell, its acquisition of the metabolic screening business of Pediatrix Medical Group and its $650 million acquisition of Packard Bioscience;
  • Arlington Tankers Ltd. in its $2 billion merger with General Maritime;
  • Bayer AG in its acquisition of the Citracal business from Mission Pharmacal;
  • King Street Capital in connection with the $235 million initial public offering by Pandora Media;
  • Savient Pharmaceuticals in its defense against activist shareholder Tang Capital and in the $176 million sale of its Rosemont Pharmaceuticals subsidiary to Close Brothers Private Equity; and
  • Lucent in its $207 million acquisition of Riverstone Networks

Mr. Robinson repeatedly has been listed in Chambers USA: America’s Leading Lawyers for Business and The Best Lawyers in America. He is the only corporate lawyer based in New England listed in Lawdragon 500 Leading Lawyers in America. In 2013, Mr. Robinson was named by The M&A Advisor as one of the top 40 M&A professionals under the age of 40 in the United States. In 2011, he was named by the Boston Business Journal as one of its "40 under 40" business and civic leaders in the city of Boston. Mr. Robinson is a member of the board of fellows of Harvard Medical School, an overseer of the Boston Symphony Orchestra and a former member of the board of directors of the Massachusetts Chapter of the March of Dimes.

Mr. Robinson also is a member of the board of directors of Project Step, a nonprofit organization that seeks to identify musically talented children from underrepresented Boston communities, provide them with comprehensive music and string instruction, and prepare them to compete and succeed as professionals in the world of classical music.

Credentials

Education

  • J.D., Harvard Law School, 1999
  • B.A., University of Pennsylvania, 1996

Admissions

  • Massachusetts
  • New York

Experience

  • Law Clerk, Hon. J. Curtis Joyner, U.S. District Court for the Eastern District of Pennsylvania

Graham Robinson

Partner, Mergers and Acquisitions
graham.robinson@skadden.com